AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
- Details
- Category: AstraZeneca

Bayer Foundation announces Science Awards winners of 2024
- Details
- Category: Bayer

GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
- Details
- Category: GlaxoSmithKline

Bayer and Dewpoint Therapeutics sign licensing agreement for heart disease program
- Details
- Category: Bayer

U.S. FDA approves Pfizer's RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease
- Details
- Category: Pfizer

Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
- Details
- Category: Roche

The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema (DME) treated with Vabysmo who identify as African American, Black, Hispanic and Latino.
Bayer submits EU marketing authorization application for elinzanetant to treat moderate to severe vasomotor symptoms
- Details
- Category: Bayer

Recent survey showed that 67% of European women reported vasomotor symptoms during menopause transition.
More Pharma News ...
- Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
- Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma
- BlueRock Therapeutics' investigational cell therapy bemdaneprocel for Parkinson's disease shows positive data at 24-months
- Bayer Co.Lab Shanghai opens as part of global expansion of life science incubator network
- FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
- Pfizer highlights diverse oncology oortfolio and combination approaches at ESMO 2024
- Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in oncology